Advertisement

Picture Berlin Partner Health Capital Computational Biology 2022 650x100px
Organisation › Details

AC Immune S.A. (Nasdaq: ACIU)

AC Immune SA is a Swiss-based biopharmaceutical company and a leader in Alzheimer´s disease drug development. AC Immune develops innovative therapeutics with "best in class" potential against Alzheimer´s disease and other conformational diseases along three axes: vaccines, antibodies and small molecules. The anti-Abeta antibody (crenezumab) for passive immunization is partnered with Genentech and is in Phase II development; it has been selected for the first groundbreaking Alzheimer's prevention trial. The company pursues the clinical development of the vaccines ACI-24 and ACI-35. These three clinical programs are focused on Alzheimer's disease, and are backed by a rich portfolio of preclinical compounds. A preclinical stage anti-Tau antibody is also partnered with Genentech. The therapeutic molecules are leveraged for Alzheimer´s disease diagnostic and other central nervous system and non-CNS diseases, such as Glaucoma and Down syndrome. Since its foundation in 2003, AC Immune has raised CHF 84 million from private investors. *

 

Period Start 2003-02-01 established
Products Industry CNS drug
  Industry 2 crenezumab
Person Person Hornstein, Jörg (Lundbeck 202209– CFO before AC Immune + Theo Müller Group + Merck KGaA)
     
Region Region Lausanne VD
  Country Switzerland
  Street EPFL Innovation Park, Building B
  City 1015 Lausanne VD
  Tel +41-21-6939121
    Address record changed: 2020-12-02
     
Basic data Employees D: 101 to 500 (2018-12-31)
  Currency CHF
  Annual sales 7,194,000 (revenue, toal (2018) 2018-12-31)
  Profit -50,951,000 (2018-12-31)
  Cash 262,500,000 (2020-06-30)
     
    * Document for �About Section�: 
     
   
Record changed: 2022-04-08

Advertisement

Picture EBD Group BIO-Europe 2022 Leipzig 650x200px

More documents for AC Immune S.A. (Nasdaq: ACIU)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BioPharm Amercia 2022 Boston 650x300px




» top